• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Limited Data for Plasmapheresis to Treat Post-COVID-19 Condition

August 30, 2023

The COVID-19 pandemic has caused substantial morbidity and mortality.  One study estimates that close to 13% of infected individuals experience post-COVID symptoms (“long-COVID”) lasting at least 12 weeks following infection.  One theory behind the pathophysiology of the post-COVID condition (PCC) is that the symptoms are caused by “microclots” composed of amyloid and fibrin and or fibrinogen [fibrin(ogen)] circulating in the blood, and some institutions are performing plasmapheresis to remove these particles.  To investigate whether these amyloid fibrin(ogen) particles could cause PCC and whether plasmapheresis is an effective treatment, researchers from the Cochrane Library performed a systematic review.  Only five studies, however, were identified which assessed whether amyloid fibrin(ogen) particles were present in the blood of individuals with PCC.  Amyloid fibrin(ogen) particles were found not only in people with PCC but also in heathy individuals and people with type-2 diabetes.  Furthermore, no randomized clinical trials were identified assessing the safety or efficacy of plasmapheresis to remove amyloid fibrin(ogen) particles.  Further research is needed on the causes of PCC and effective treatment options.

Reference:

Fox T, Hunt BJ, Ariens RAS, Towers GJ, et al.  Plasmapheresis to remove amyloid fibrin(ogen) particles for treating post-COVID-19 condition.  Cochrane Database of Systematic Reviews 2023, Issue 7.  Art. No.: CD015775

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • Stored Whole Blood Treated with Pathogen Reduction Acceptable for Transfusion

  • Transfusion Patterns After CAR T-Cell Therapy for Large B-Cell Lymphoma

  • Restrictive Transfusions Threshold Safe for Cardiac Surgery Patients

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley